Psoriasis, a chronic autoimmune skin disease, goes beyond visible symptoms. Emerging evidence suggests a strong link between psoriasis and an increased risk of cardiovascular disease (CVD), the leading cause of death globally. This review delves into the potential mechanisms underlying this connection, exploring the role of inflammation, metabolic dysfunction, and shared risk factors. We discuss the impact of psoriasis severity on CVD risk and highlight the potential benefits of psoriasis treatment in reducing cardiovascular complications. By understanding this interlink, healthcare professionals can provide more comprehensive care for patients with psoriasis.
Psoriasis is a common autoimmune condition characterized by red, scaly patches on the skin. While traditionally viewed as a dermatological issue, recent research reveals a more complex picture. People with psoriasis have a significantly increased risk of developing cardiovascular disease (CVD), the leading cause of death worldwide. This article explores the potential mechanisms that bridge the gap between these seemingly disparate conditions.
Chronic inflammation is a common thread linking psoriasis and CVD. In psoriasis, the immune system mistakenly attacks healthy skin cells, leading to inflammation. This systemic inflammation can spill over and affect the cardiovascular system, promoting:
Endothelial dysfunction: Damage to the inner lining of blood vessels, hindering their ability to relax and increasing the risk of atherosclerosis (plaque buildup).
Increased blood clotting: Psoriasis can trigger changes in blood clotting factors, raising the risk of heart attack and stroke.
Metabolic abnormalities: Chronic inflammation is associated with insulin resistance and dyslipidemia (abnormal cholesterol levels), further increasing CVD risk.
Several factors contribute to both psoriasis and CVD, suggesting a potential underlying vulnerability:
Genetics: Certain genes predispose individuals to both conditions.
Obesity and metabolic syndrome: These conditions contribute to both psoriasis and CVD through inflammatory pathways.
Smoking: Smoking is a well-established risk factor for both psoriasis and CVD by increasing inflammation and damaging blood vessels.
Studies suggest a dose-dependent relationship between psoriasis severity and CVD risk. Patients with more severe psoriasis, particularly those with widespread involvement, have a higher risk of cardiovascular complications. This highlights the importance of early diagnosis and effective treatment of psoriasis.
The good news is that managing psoriasis may offer cardiovascular benefits. Emerging evidence suggests that:
Treating moderate to severe psoriasis with certain systemic medications may be associated with a reduced risk of CVD events.
Lifestyle modifications like maintaining a healthy weight, eating a balanced diet, and exercising regularly are crucial for managing both psoriasis and CVD risk factors.
The link between psoriasis and CVD underscores the need for a more holistic approach to managing this chronic skin condition. Early diagnosis, effective treatment, and addressing shared risk factors can improve cardiovascular health and overall well-being for patients with psoriasis. Further research is crucial to elucidate the precise mechanisms at play and develop targeted therapeutic strategies to address this critical public health concern.
1.
More Positive Survival Data in Lung Cancer With Perioperative Therapy
2.
Upfront TKI for Bone-Predominant RCC Tops Single-Agent Immunotherapy
3.
Study finds 10% of pediatric blood cancers may stem from medical imaging radiation
4.
For the creation of cutting-edge targeted radionuclide therapies in oncology, Bayer and Bicycle Therapeutics work together.
5.
Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.
1.
Case Study: Artificial Intelligence in Early Cancer Detection
2.
Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment
3.
What is Mullerian and How Does it Affect Your Health
4.
AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies
5.
Is p53 the Missing Puzzle Piece? Exploring Its Polymorphisms in Cervical Cancer Risk
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Should We Use DARA Up Front As First-Line Therapy in MM?
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part IV
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
4.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation